Final Impact of Anti-Vascular Endothelial Growth Factor Treatment in Age-related Macular Degeneration
10.3341/jkos.2018.59.11.1039
- Author:
Jangmi YANG
1
;
Sang Jin SHIN
;
Jae Kyung SUH
;
Songhee CHO
;
Hajin TCHOE
;
Min Joo KANG
;
Donghyun JEE
Author Information
1. Office of Economic Evaluation Research, National Evidence Based Healthcare Collaborating Agency, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Age-related macular degeneration;
Anti-vascular endothelial growth factor;
Ranibizumab
- MeSH:
Bevacizumab;
Budgets;
Delivery of Health Care;
Endothelial Growth Factors;
Humans;
Insurance;
Insurance, Health;
Macular Degeneration;
National Health Programs;
Ranibizumab;
Standard of Care;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2018;59(11):1039-1048
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the effects of anti-vascular endothelial growth factor (VEGF) treatment on the healthcare-related finances of patients with age-related macular degeneration. METHODS: Changes in health care financing due to newly introduced benefit standards were predicted over the coming 5-year period (2018–2022). We also analyzed the financial impact of scenarios in which agents similar to anti-VEGF, such as the over-licensed drug bevacizumab, were introduced. For this purpose, the future number of patients receiving anti-VEGF treatments was estimated for various scenarios based on National Health Insurance Corporation claims data followed by an estimate of the financial burden. RESULTS: In the case of age-related macular degeneration, the current standard of care (14 times in a lifetime) was maintained in scenario 1. In 2018, the insurance budget for the coming 5-year period was estimated at approximately 440.3 billion won. The insurance cost for that period was estimated at approximately 560.1 billion won under the revised standard of December 2017 (scenario 2). For scenarios wherein, after 2020, similar treatments (scenario 3) and bevacizumab (scenario 4) were introduced, the estimated health insurance costs were 521 billion won and 419.7 billion won, respectively. CONCLUSIONS: Health insurance costs are projected to increase substantially due to the elimination of the 14 time pay standard; however, the actual budget will only moderately increase, due to new limitations of visual acuity ≤ 0.1 or in case of scarring/ atrophic lesions. Clinically similar agents and bevacizumab could be considered as alternatives to anti-VEGF treatment for age-related macular degeneration.
